帕比司他单药巩固治疗改善多发性骨髓瘤移植后反应不佳的II期试验
这项II期试验评估了帕比司他单药对自体移植后未达完全缓解的多发性骨髓瘤患者的疗效。应答者T淋巴细胞组蛋白乙酰化增加,并伴有免疫亚群和转录组变化,提示这些可作为药效学标志物。
要点
- 帕比司他单药可使48%移植后反应不佳的多发性骨髓瘤患者加深反应。
- 应答者T淋巴细胞组蛋白乙酰化较基线升高,非应答者无变化。
- 非应答者CD127+CD8+T细胞比例和CD4:CD8比值下降更显著。
核心结论
- 帕比司他单药在多发性骨髓瘤移植后反应不佳患者中有效,可改善反应深度。
- 淋巴细胞组蛋白乙酰化、免疫亚群调节和转录变化可作为临床获益的药效学标志物。
研究设计与样本
- II期临床试验,纳入25例自体移植后未达完全缓解的多发性骨髓瘤患者。
- 帕比司他45 mg每周三次,隔周给药,28天为一周期,移植后8-12周开始。
主要发现
- 非应答者较应答者,3和6周期后CD127+CD8+T细胞比例和CD4:CD8比值下降更显著。
- 全骨髓RNA-seq仅应答者出现广泛转录变化,基线差异基因涉及核糖体生物合成、氧化磷酸化和代谢通路。
临床怎么用
- 对于自体移植后未达完全缓解的多发性骨髓瘤患者,可考虑帕比司他单药巩固治疗。
- 治疗中可监测淋巴细胞组蛋白乙酰化、免疫亚群和转录变化作为药效学标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Panobinostat is a pan-deacetylase inhibitor that modulates the expression of oncogenic and immune-mediating genes involved in tumour cell growth and survival. We evaluated panobinostat-induced post-transplant responses and identified correlative biomarkers in patients with multiple myeloma who had failed to achieve a complete response after autologous transplantation. Patients received panobinostat 45 mg administered three-times weekly (TIW) on alternate weeks of 28-day cycles commencing 8-12 weeks post-transplant. Twelve of 25 patients (48%) improved their depth of response after a median (range) of 4·3 (1·9-9·7) months of panobinostat. In responders, T-lymphocyte histone acetylation increased after both three cycles (P < 0·05) and six cycles (P < 0·01) of panobinostat when compared to baseline, with no differences in non-responders. The reduction in the proportion of CD127+ CD8+ T cells and CD4:CD8 ratio was significantly greater, after three and six cycles of panobinostat compared to pre-transplant, in non-responders when compared to responders. Whole marrow RNA-seq revealed widespread transcriptional changes only in responders with baseline differences in genes involved in ribosome biogenesis, oxidative phosphorylation and metabolic pathways. This study confirmed the efficacy of panobinostat as a single agent in multiple myeloma and established acetylation of lymphocyte histones, modulation of immune subsets and transcriptional changes as pharmacodynamic biomarkers of clinical benefit.
引用
- Mithraprabhu S, Kalff A, Gartlan KH, et al. Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma. Br J Haematol. 2020. PMID: 32945549. doi:10.1111/bjh.17080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。